Gefapixant in two randomised dose-escalation studies in chronic cough.

Jaclyn Ann SmithMichael M KittPeter ButeraSteven A SmithYuping LiZhi Jin XuKimberley HoltShilpi SenMandel R SherAnthony P Ford

Published in: The European respiratory journal (2020)

P2X3 antagonism with gefapixant demonstrates anti-tussive efficacy and improved tolerability at lower doses than previously investigated. Studies of longer duration are warranted.

Keyphrases

open label
clinical trial
case control
double blind
placebo controlled
study protocol
high resolution